Exemis 25 mg (Exemestane) Tablets

Exemis 25 mg (Exemestane) Tablets – Advanced Hormone Therapy for Breast Cancer

Overview

Exemis 25 mg contains Exemestane, a powerful aromatase inhibitor designed specifically for the treatment of hormone-receptor positive breast cancer in postmenopausal women. Manufactured by the renowned Eskayef Pharmaceuticals Ltd and supplied  globally by Saif Pharma, Exemis represents a critical advancement in hormone therapy for breast cancer patients. This highly effective medication works by significantly reducing estrogen levels in the body, helping to stop or slow the growth of estrogen-dependent tumor cells.

Mechanism of Action

Exemestane functions through an innovative “suicide inhibition” mechanism that permanently inactivates the aromatase enzyme. As a steroidal aromatase inactivator structurally related to the natural substrate androstenedione, Exemestane:

1. Acts as a false substrate for the aromatase enzyme
2. Is processed to an intermediate that binds irreversibly to the active site of the enzyme
3. Causes permanent inactivation of the aromatase, preventing it from producing estrogen
4. Significantly lowers circulating estrogen concentrations in postmenopausal women

This specific targeting of the aromatase enzyme occurs without affecting adrenal biosynthesis of corticosteroids or aldosterone, and has no detectable impact on other enzymes involved in the steroidogenic pathway at therapeutic concentrations.

Clinical Applications

Exemis 25 mg is indicated for two primary clinical applications in postmenopausal women with hormone-receptor positive breast cancer:

• Adjuvant Treatment: For postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of Tamoxifen and are switched to Exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy
• Advanced Breast Cancer: For treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy

The medication has demonstrated significant efficacy in both reducing recurrence rates in early-stage breast cancer and controlling disease progression in advanced cases.

Dosage & Administration

The recommended dosage of Exemis is one 25 mg tablet taken once daily after a meal. This simple, once-daily oral administration enhances patient compliance and convenience during long-term treatment regimens. The after-meal recommendation optimizes absorption and bioavailability of the active ingredient.

Product Quality Assurance

Manufactured by Eskayef Pharmaceuticals Ltd, a leading pharmaceutical company with over three decades of excellence, Exemis adheres to stringent quality control standards. Each film-coated tablet contains precisely 25 mg of Exemestane BP, ensuring consistent potency and efficacy. The product is packaged in convenient strips of 10 tablets, with three strips (30 tablets) per box, providing a month’s supply in each package.

Global Availability

Through Saif Pharma’s extensive supplier network spanning over 60 countries, Exemis 25 mg is accessible to breast cancer patients worldwide, including major markets such as:

• United States
• Canada
• Saudi Arabia
• United Arab Emirates
• China
• India
• Pakistan

This global reach ensures that patients across diverse geographic regions can access this important treatment option consistently.

Advantages of Exemis

1. Irreversible Inhibition: The permanent inactivation of aromatase provides more complete estrogen suppression compared to reversible inhibitors
2. Specific Action: Targets aromatase without affecting other steroidogenic enzymes or adrenal function
3. Convenient Dosing: Simple once-daily administration enhances treatment adherence
4. Established Efficacy: Proven effectiveness in both early and advanced breast cancer settings
5. Quality Manufacturing: Produced by Eskayef Pharmaceuticals with rigorous quality standards
6. Global Suoolier: Available worldwide through Saif Pharma’s established network
7. Cost-Effective Option: Offered at competitive pricing to improve accessibility

Important Precautions and Considerations

Safety Profile

While generally well-tolerated, patients may experience side effects including:

• Hot flushes
• Fatigue
• Arthralgia (joint pain)
• Headache
• Insomnia
• Increased sweating

Special Precautions

Healthcare providers should be aware of important considerations when prescribing Exemis:

• Bone Health: Reductions in bone mineral density (BMD) may occur over time with exemestane use, and appropriate monitoring is recommended
• Vitamin D Assessment: Routine evaluation of 25-hydroxy vitamin D levels prior to starting treatment is advised
• Drug Interactions: Strong CYP3A4 inducers (e.g., rifampicin, phenytoin, carbamazepine) may decrease exemestane exposure, potentially requiring dose adjustment
• Pregnancy and Breastfeeding: Not indicated during pregnancy or lactation due to potential risks
• Premenopausal Women: Not indicated for breast cancer treatment in premenopausal women

Storage Recommendations

For optimal stability and efficacy, Exemis should be:

• Stored below 30°C
• Protected from light and moisture
• Kept out of reach of children

About the Manufacturer

Eskayef Pharmaceuticals Ltd began its journey in 1990 when Bangladesh operations of SK&F, USA were acquired by the respected Transcom Group. For over 31 years, Eskayef has built a reputation for premium quality pharmaceuticals, serving both domestic and international markets with world-class medicines.

About the Supplier

Founded in 2014, Saif Pharma has established itself as a leading supplier, trader, and supplier of oncology medicines. With a mission centered on providing high-quality, affordable cancer treatments, Saif Pharma has earned a prestigious market position by prioritizing dependability and patient access. Their extensive global network ensures that vital medications like Exemis reach patients worldwide, reducing suffering and improving treatment outcomes.

Commitment to Cancer Care

Both Eskayef Pharmaceuticals and Saif Pharma share a commitment to advancing cancer care through high-quality, accessible medications. Exemis 25 mg represents this shared mission, offering a scientifically advanced treatment option that can significantly improve outcomes for postmenopausal women with hormone-receptor positive breast cancer.

For more information about Exemis 25 mg (Exemestane) or to inquire about availability in your region, please visit www.saifpharma.com or consult with your healthcare provider.